Efficacy of dapagliflozin in improving arrhythmia-related outcomes after ablation for atrial fibrillation: a retrospective single-center study.
Clin Res Cardiol
; 113(6): 924-932, 2024 Jun.
Article
em En
| MEDLINE
| ID: mdl-38358416
ABSTRACT
BACKGROUND:
Atrial fibrillation (AF) is a widespread type of sustained arrhythmia that poses significant health risks. Catheter ablation is the preferred treatment; however, arrhythmia recurrence remains challenging. Sodium-glucose co-transporter 2 inhibitors, particularly dapagliflozin (DAPA), have exhibited cardiovascular benefits. However, to date, the influence of these inhibitors on AF post-ablation remains unclear.METHODS:
We analyzed the records of 272 patients who underwent catheter ablation for AF from January 2018 to December 2022. Patients were divided into the control (n = 199) and DAPA (n = 73) groups based on DAPA prescription post-ablation. The primary outcome was total atrial arrhythmia recurrence after a 3-month blanking period.RESULTS:
The mean age was 72.19 ± 5.45 years; 86.8% of the patients were men. At 18 months post-ablation, 36.2% and 9.5% of the patients in the control and DAPA groups, respectively, reported atrial arrhythmia. Multivariate analysis revealed that DAPA use was associated with a significantly reduced risk of arrhythmia recurrence (adjusted hazard ratio [aHR] 0.15, 95% confidence interval [CI] 0.07-0.32, p < 0.001). After propensity score-matching (PSM) in 65 pairs, arrhythmia recurrence was lower in the DAPA group compared with the control (8.3% versus 30.8%, aHR 0.17, 95% CI 0.06-0.51, p = 0.002). Freedom from total arrhythmia recurrence was significantly higher in the DAPA group compared with the control group in both the overall and PSM population (log-rank test p < 0.01).CONCLUSION:
DAPA administration post-ablation was associated with significantly reduced atrial arrhythmia recurrence rates, indicating its potential as an adjunct therapy for enhancing the success of AF ablation.Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Recidiva
/
Fibrilação Atrial
/
Compostos Benzidrílicos
/
Ablação por Cateter
/
Inibidores do Transportador 2 de Sódio-Glicose
/
Glucosídeos
Tipo de estudo:
Risk_factors_studies
Limite:
Aged
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Clin Res Cardiol
/
Clin. res. cardiol
/
Clinical research in cardiology
Assunto da revista:
CARDIOLOGIA
Ano de publicação:
2024
Tipo de documento:
Article